Acta Oncol 2019 Oct
45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
Related Questions
-Are there settings where group II disease does not need RT?-Are there additional genetic alterations in fusion negative RMS patients that can be used...
New answer by Radiation Oncologist at University of Florida College of Medicine (October 1, 2020)
The guiding principles of disease control while maintaining form, function, and quality of life drive the decision-making and management for patients with rhabdomyosarcoma.Reg...